EGFR Lung Cancer Patient Story
This lung cancer diagnosis at a glance
- Biomarkers
- EGFR mutation
- Sex
- Male
- Treatment
- chemotherapy, targeted therapy and a clinical trial
- Outcome
- Care Ongoing
Treatment course, step by step
- Earlier treatment sequence was chemotherapy, then Tarceva/erlotinib, then Giotrif/afatinib
- She then joined an AZD9291 clinical trial for EGFR-mutated lung cancer
- July visit checked AZD9291 side effects and safety labs
- Blood tests and checks were going well, with no major side effects
- Next CT was planned for late August to see whether tumors were responding.
What happened, in summary
This Noxte post was written from Asturias, where the patient had gone after an oncology visit in Majadahonda. The visit on 15 July focused on toxicity monitoring for AZD9291, the study drug he was receiving through a clinical trial. The checks were reassuring: blood work and other tests were going well, and he was not having major side effects. Whether the drug was controlling the tumor still required patience. A CT was planned for late August, and he was cautious about drawing conclusions before imaging. Still, based on his symptoms, he felt the treatment might be helping. He described his lung cancer journey as a sequence of steps: first chemotherapy, then erlotinib/Tarceva, then afatinib/Giotrif, and now AZD9291, a TKI therapy connected to EGFR-mutated lung cancer. He was clear that none of these treatments felt curative, but each could place another obstacle in the cancer’s path and buy more time. As of 20 July 2016, he felt fortunate to have access to a newer targeted therapy and to be well enough to spend part of the summer walking, going to the beach, and enjoying Asturias while waiting for the next scan.
Where this story comes from
This is a lay summary of an account first published by Noxte (Blog Cáncer de Pulmón). Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer